BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saavedra D, Crombet T. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Front Immunol 2017;8:269. [PMID: 28348561 DOI: 10.3389/fimmu.2017.00269] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Schoenfeld NC. Vivir En Cronicidad: Terminal Living through Cuban Cancer Vaccines. Med Anthropol 2021;:1-15. [PMID: 33684318 DOI: 10.1080/01459740.2021.1891053] [Reference Citation Analysis]
2 Xiong AW, Fang JM, Ren SX, Li W, Wang J, Zhao Y, Chen GY, Xu Q, Zhou CC. A Novel Combined Conjugate Therapeutic Cancer Vaccine, Recombinant EGF-CRM197, in Patients With Advanced Solid Tumors: A Phase I Clinical Study. Front Oncol 2021;11:745699. [PMID: 34804932 DOI: 10.3389/fonc.2021.745699] [Reference Citation Analysis]
3 Suárez GM, Catalá M, Peña Y, Portela S, Añé-Kourí AL, González A, Lorenzo-Luaces P, Díaz M, Molina MLA, Pereira K, Hernández JC, Ramos R, Reyes MC, Ledón N, Mazorra Z, Crombet T, Lage A, Saavedra D. Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Front Oncol 2022;12:823287. [PMID: 35155258 DOI: 10.3389/fonc.2022.823287] [Reference Citation Analysis]
4 Zuo J, Wen M, Li S, Lv X, Wang L, Ai X, Lei M. Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9. Oncol Lett 2017;14:7513-21. [PMID: 29344197 DOI: 10.3892/ol.2017.7168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
5 Guardiola S, Varese M, Sánchez-navarro M, Giralt E. A Third Shot at EGFR: New Opportunities in Cancer Therapy. Trends in Pharmacological Sciences 2019;40:941-55. [DOI: 10.1016/j.tips.2019.10.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
6 Saavedra D, Fuertes SA, Suárez GM, González A, Lorenzo-Luaces P, García B, Aznar E, Mazorra Z, Crombet T, Speiser DE, Lage A. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. Exp Gerontol 2019;124:110633. [PMID: 31207285 DOI: 10.1016/j.exger.2019.110633] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
7 Wieleba I, Wojas-Krawczyk K, Krawczyk P, Milanowski J. Clinical Application Perspectives of Lung Cancers 3D Tumor Microenvironment Models for In Vitro Cultures. Int J Mol Sci 2022;23:2261. [PMID: 35216378 DOI: 10.3390/ijms23042261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Oliveres H, Caglevic C, Passiglia F, Taverna S, Smits E, Rolfo C. Vaccine and immune cell therapy in non-small cell lung cancer. J Thorac Dis 2018;10:S1602-14. [PMID: 29951309 DOI: 10.21037/jtd.2018.05.134] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
9 McCaffery JN, Fonseca JA, Singh B, Cabrera-Mora M, Bohannon C, Jacob J, Arévalo-Herrera M, Moreno A. A Multi-Stage Plasmodium vivax Malaria Vaccine Candidate Able to Induce Long-Lived Antibody Responses Against Blood Stage Parasites and Robust Transmission-Blocking Activity. Front Cell Infect Microbiol 2019;9:135. [PMID: 31119106 DOI: 10.3389/fcimb.2019.00135] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
10 Huang Y, Zou Y, Lin L, Zheng R. Ginsenoside Rg1 Activates Dendritic Cells and Acts as a Vaccine Adjuvant Inducing Protective Cellular Responses Against Lymphomas. DNA and Cell Biology 2017;36:1168-77. [DOI: 10.1089/dna.2017.3923] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
11 Stolk DA, de Haas A, Vree J, Duinkerken S, Lübbers J, van de Ven R, Ambrosini M, Kalay H, Bruijns S, van der Vliet HJ, de Gruijl TD, van Kooyk Y. Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses. Front Immunol 2020;11:990. [PMID: 32536918 DOI: 10.3389/fimmu.2020.00990] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
12 Cortés-jofré M, Uranga R, Torres Pombert A, Arango Prado MDC, Caballero Aguirrechu I, Pacheco C, Ortiz Reyes RM, Chuecas F, Mas Bermejo PI; Cochrane Lung Cancer Group. Therapeutic vaccines for advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013377] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Filipić B, Stojić-vukanić Z. Active immunotherapy of cancer: An overview of therapeutic vaccines. Arhiv za farmaciju 2019;69:490-506. [DOI: 10.5937/arhfarm1906490f] [Reference Citation Analysis]
14 Suárez GM, Añé-Kourí AL, González A, Lorenzo-Luaces P, Neninger E, Salomón EE, Cordero L, Catalá M, Ledón N, Pereira K, Sánchez MG, García B, Crombet T, Mazorra Z, Saavedra D, Lage A. Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer. Cancer Immunol Immunother 2021;70:1735-43. [PMID: 33388995 DOI: 10.1007/s00262-020-02823-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Brahmer JR, Johnson ML, Cobo M, Viteri S, Sarto JC, Sukari A, Awad MM, Salgia R, Papadimitrakopoulou VA, Rajan A, Bandyopadhyay N, Allred AJ, Wade M, Mason GE, Zudaire E, Knoblauch RE, Stone N, Lorenzi MV, Hassan R. JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies. JTO Clin Res Rep 2021;2:100103. [PMID: 34589981 DOI: 10.1016/j.jtocrr.2020.100103] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Popa X, García B, Fuentes KP, Huerta V, Alvarez K, Viada CE, Neninger E, Rodríguez PC, González Z, González A, Crombet T, Mazorra Z. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule. Oncoimmunology 2020;9:1762465. [PMID: 32923124 DOI: 10.1080/2162402X.2020.1762465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 González-martínez DA, González Ruíz G, Luzardo Lorenzo MDC, Bordallo-león F, Hechavarría Luna Y, Cazañas Quintana Y, González-martínez E, León K, González Palomo A, García Artalejo JA, Moran-mirabal J. Hydroxyapatite Nanoparticles as a Potential Long-Term Treatment of Cancer of Epithelial Origin. ACS Appl Nano Mater 2022;5:6159-70. [DOI: 10.1021/acsanm.2c00021] [Reference Citation Analysis]
18 Saavedra D, Neninger E, Rodriguez C, Viada C, Mazorra Z, Lage A, Crombet T. CIMAvax-EGF: Toward long-term survival of advanced NSCLC. Semin Oncol 2018;45:34-40. [PMID: 30318082 DOI: 10.1053/j.seminoncol.2018.04.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Razaghi A, Heimann K, Schaeffer PM, Gibson SB. Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies. Apoptosis 2018;23:93-112. [PMID: 29322476 DOI: 10.1007/s10495-018-1440-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
20 Kaur J, Elms J, Munn AL, Good D, Wei MQ. Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy. Crit Rev Oncol Hematol 2021;164:103417. [PMID: 34242772 DOI: 10.1016/j.critrevonc.2021.103417] [Reference Citation Analysis]
21 Xue T, Zhao X, Zhao K, Lu Y, Yao J, Ji X. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy. Curr Probl Cancer 2021;:100791. [PMID: 34538649 DOI: 10.1016/j.currproblcancer.2021.100791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Crombet Ramos T, Santos Morales O, Dy GK, León Monzón K, Lage Dávila A. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. Front Oncol 2021;11:639745. [PMID: 34211836 DOI: 10.3389/fonc.2021.639745] [Reference Citation Analysis]
23 Reginald K, Chan Y, Plebanski M, Poh CL. Development of Peptide Vaccines in Dengue. Curr Pharm Des 2018;24:1157-73. [PMID: 28914200 DOI: 10.2174/1381612823666170913163904] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
24 Beyaert S, Machiels JP, Schmitz S. Vaccine-Based Immunotherapy for Head and Neck Cancers. Cancers (Basel) 2021;13:6041. [PMID: 34885150 DOI: 10.3390/cancers13236041] [Reference Citation Analysis]
25 Morera-díaz Y, Gavilondo JV, Bequet-romero M, Sánchez Ramírez J, Hernández-bernal F, Selman-housein K, Perez L, Ayala-ávila M. Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside. Seminars in Oncology 2018;45:68-74. [DOI: 10.1053/j.seminoncol.2018.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Ren X, Li Y, Nishimura C, Zang X. Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. Genes Dis 2022;9:1181-93. [PMID: 35873032 DOI: 10.1016/j.gendis.2021.08.009] [Reference Citation Analysis]
27 Dey Sarkar R, Sinha S, Biswas N. Manipulation of Inflammasome: A Promising Approach Towards Immunotherapy of Lung Cancer. Int Rev Immunol 2021;40:171-82. [PMID: 33508984 DOI: 10.1080/08830185.2021.1876044] [Reference Citation Analysis]
28 Qiao M, Jiang T, Liu X, Mao S, Zhou F, Li X, Zhao C, Chen X, Su C, Ren S, Zhou C. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn? J Thorac Oncol 2021;16:1267-88. [PMID: 33915248 DOI: 10.1016/j.jtho.2021.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Akache B, Stark FC, Agbayani G, Renner TM, McCluskie MJ. Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines. Methods Mol Biol 2022;2412:179-231. [PMID: 34918246 DOI: 10.1007/978-1-0716-1892-9_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, Genova C. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. Expert Opin Biol Ther 2018;18:829-35. [PMID: 29936901 DOI: 10.1080/14712598.2018.1492539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
31 Zappasodi R, Merghoub T, Wolchok JD. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell. 2018;33:581-598. [PMID: 29634946 DOI: 10.1016/j.ccell.2018.03.005] [Cited by in Crossref: 208] [Cited by in F6Publishing: 202] [Article Influence: 69.3] [Reference Citation Analysis]
32 Pérez NR, Pérez CV, Trujillo NM, Suárez IM, Torres EM, Estévez IF, Sao MP, Rojo YT, González VGS. [Science and technological innovation in health in Cuba: results in selected problemsCiência e inovação tecnológica em saúde em Cuba: resultados em problemas selecionados]. Rev Panam Salud Publica 2018;42:e32. [PMID: 31093061 DOI: 10.26633/RPSP.2018.32] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Spagnuolo A, Gridelli C. Combining immunotherapies to treat non-small cell lung cancer. Expert Rev Respir Med 2019;13:621-34. [PMID: 31116072 DOI: 10.1080/17476348.2019.1623027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]